7-year-old Maverick has a rare genetic disorder that severely limits his vision. Now, a medication called Luxturna – the first gene therapy approved by the FDA – has the potential to substantially improve his sight, via an injection of a gene-carrying virus underneath his retina.
Watch more Prognosis:
Like this video? Subscribe to Bloomberg on YouTube: http://www.youtube.com/Bloomberg?sub_confirmation=1
Bloomberg is the First Word in business news, delivering breaking news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com
Connect with us on…